Atrion Corporation (NASDAQ:ATRI) released its earnings results on Tuesday, August 8th. The medical instruments supplier reported $5.40 EPS for the quarter, Bloomberg Earnings reports. Atrion Corporation had a return on equity of 18.67% and a net margin of 22.75%. The company had revenue of $36.16 million for the quarter.

Shares of Atrion Corporation (NASDAQ:ATRI) traded down 0.61% during trading on Friday, hitting $616.70. The company had a trading volume of 2,977 shares. Atrion Corporation has a 52 week low of $393.96 and a 52 week high of $691.95. The company has a market capitalization of $1.14 billion, a P/E ratio of 34.55 and a beta of 0.91. The stock’s 50-day moving average price is $639.17 and its 200 day moving average price is $543.18.

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 29th. Investors of record on Friday, September 15th will be issued a dividend of $1.20 per share. This represents a $4.80 dividend on an annualized basis and a dividend yield of 0.78%. The ex-dividend date of this dividend is Thursday, September 14th. This is an increase from Atrion Corporation’s previous quarterly dividend of $1.05. Atrion Corporation’s dividend payout ratio is currently 23.52%.

In related news, Chairman Emile A. Battat sold 100 shares of the firm’s stock in a transaction dated Friday, June 9th. The stock was sold at an average price of $585.50, for a total transaction of $58,550.00. Following the transaction, the chairman now owns 149,081 shares of the company’s stock, valued at $87,286,925.50. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Chairman Emile A. Battat sold 1,217 shares of the firm’s stock in a transaction dated Friday, June 2nd. The stock was sold at an average price of $564.04, for a total value of $686,436.68. Following the transaction, the chairman now directly owns 150,797 shares in the company, valued at approximately $85,055,539.88. The disclosure for this sale can be found here. In the last three months, insiders have sold 2,671 shares of company stock worth $1,508,827. Corporate insiders own 24.23% of the company’s stock.

Separately, BidaskClub lowered Atrion Corporation from a “strong-buy” rating to a “buy” rating in a report on Thursday, July 27th.

ILLEGAL ACTIVITY NOTICE: “Atrion Corporation (ATRI) Announces Quarterly Earnings Results” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another website, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this story can be viewed at

About Atrion Corporation

Atrion Corporation (Atrion) is engaged in developing and manufacturing products, primarily for medical applications. The Company’s medical products range from fluid delivery devices to ophthalmic and cardiovascular products. Its fluid delivery products include valves that promote infection control and needle safety.

Earnings History for Atrion Corporation (NASDAQ:ATRI)

Receive News & Stock Ratings for Atrion Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion Corporation and related stocks with our FREE daily email newsletter.